First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study

Category Primary study
JournalFront. Oncol.
Year 2025
This article has no abstract
Epistemonikos ID: 7ef3c3996ed049c76ba014b87a5b3ba32c12d378
First added on: Oct 17, 2025